Market Size & Trends

The growing demand for effective treatment solutions in North America and Europe is driving the market size of intravenous infusion pumps to USD 4.45 billion by 2024. A projected CAGR of 8.10% from 2025 to 2030 underscores the increasing need for precise and controlled delivery systems, particularly in managing chronic diseases such as respiratory diseases, stroke, diabetes, cancer, and cardiovascular diseases, which pose a significant threat to public health in these regions. Notably, cardiovascular disease remains a leading cause of death in Europe and North America, with an estimated 129 million individuals in the US alone living with at least one major chronic condition. To mitigate this risk, intravenous infusion pumps have emerged as a crucial tool, providing a secure means of administering medication via radiation therapy or chemotherapy while ensuring precise dosages are maintained. By minimizing medication errors – a pressing concern in patient care – these pumps play a vital role in enhancing treatment outcomes and overall patient well-being.

 

The healthcare industry is witnessing a significant shift towards the adoption of advanced delivery systems that prioritize safety, efficiency, and standardization. One such innovation is the introduction of smart infusion pumps, which are revolutionizing the way medications are administered in hospitals. These intelligent devices come equipped with sophisticated computer software systems designed to minimize drug dosing errors. By integrating comprehensive libraries of medications, these pumps ensure accurate and secure medication administration, thereby reducing risks associated with human error. A notable example of this advancement is Mackenzie Health's successful implementation of BD Alaris EMR Interoperability in April 2024. This pioneering effort enabled seamless communication between IV infusion pumps and electronic medical records (EMRs), eliminating the need for manual programming and significantly reducing medication administration errors. Studies have shown an impressive 86% reduction in keystrokes required for infusion programming. As a result, smart infusion technologies are driving market growth by fueling hospitals' demand for interoperable and automated IV pumps. With their ability to streamline workflow efficiency and enhance patient care, these innovative systems are poised to continue making strides in the healthcare sector.

Regulatory approvals of advanced infusion pump technologies are playing a pivotal role in shaping the intravenous infusion pump market, ultimately benefiting patient safety, efficiency, and connectivity in healthcare settings. Baxter International Inc., a prominent player in this space, has recently gained FDA 510(k) clearance for its Novum IQ large volume infusion pump with Dose IQ Safety Software. This significant milestone not only expands the company's Novum IQ Infusion Platform but also enables clinicians to seamlessly utilize both large volume and syringe pumps as part of an integrated system. By fostering a single, connected platform across various care settings, this innovation significantly enhances workflow efficiency while minimizing medication errors. As hospitals continue to adopt smart, interoperable infusion technologies, the demand for next-generation IV pumps is poised for substantial growth.

Market Concentration & Characteristics

The pharmaceutical industry is experiencing a surge in technological advancements, transforming the way medical devices like infusion pumps are designed, manufactured, and used. In recent years, smart infusion pumps have gained significant traction in both North America and Europe, with companies investing heavily in research and development to bring forth innovative solutions. To ensure regulatory compliance, manufacturers are also working closely with authorities to secure approvals for new infusion devices, further propelling the industry towards a more efficient and effective healthcare landscape.

Several key players, including ICU Medical, Inc., are engaged in collaborative efforts with top-tier organizations. By leveraging strategic initiatives, these companies foster a culture of innovation, expand their distribution networks, and broaden their geographic reach to bolster their market position and capitalize on the increasing demand for infusion pumps.

 

In today's fast-paced market landscape, regulatory frameworks play a pivotal role in shaping the success of products. By adhering to rigorous standards and obtaining necessary approvals, businesses can guarantee that their offerings meet high safety and efficacy benchmarks. This, in turn, instills trust among consumers and fosters a more receptive market environment. Nevertheless, the extensive approval processes often required can lead to delays in product launch and increased development expenses for manufacturers, presenting a trade-off between timeliness and quality.

As patients increasingly prioritize personalized care, alternative treatment options like subcutaneous intrathecal and enteral pumps are gaining popularity. These cutting-edge devices leverage advanced technology, seamlessly connecting to smartphones for enhanced convenience and accessibility.

As market players continue to expand their regional footprint, they're now targeting newly accessible territories through targeted partnerships with local wholesalers. Meanwhile, they're also tailoring their offerings to cater specifically to the unique healthcare needs of each area.

Product Insights

The volumetric infusion pumps segment dominated the market share of over 27.44% in 2024, underscoring their critical role in ensuring precise and regulated medication administration for patients with severe conditions. These medical devices utilize advanced electronic peristaltic pressure technology to deliver fluids with remarkable accuracy, thereby optimizing the efficiency of drug administration. Used extensively across various healthcare settings, including hospitals, home care facilities, ambulatory clinics, and outpatient infusion centers, volumetric infusion pumps play a vital role in delivering large volumes of essential medications such as hormones, antibiotics, chemotherapy drugs, and pain relievers.

The ambulatory infusion pump market is poised for significant growth over the forecast period, driven by its convenience, mobility, and reduced hospital stays. The ease of use and portability of these devices have made them an attractive option for patients requiring ongoing treatment. Recent technological advancements have further propelled market expansion, with notable examples including Moog Inc.'s CURLIN 8000 Ambulatory Infusion System, cleared by the FDA in May 2024. This system boasts a user-friendly interface, ensuring precise and continuous infusion delivery, making it an ideal solution for home infusion therapy. As the aging population and cost-saving initiatives drive home healthcare adoption, the demand for portable and user-friendly ambulatory infusion pumps is expected to rise, fueling market growth.

Get A Free Sample Research Report PDF

https://www.theresearchinsights.com/reports/north-america-and-europe-intravenous-infusion-pumps-market-238/request-sample

Disease Indication Insights

The pediatrics/neonatology segment dominated the market in 2024, accounting for 26.47% share, driven by a rise in congenital disabilities and improved medication administration facilitated by infusion pumps. The Centers for Disease Control and Prevention reports that one in every 33 babies born in the US is diagnosed with congenital disabilities annually, while the European Union sees approximately 2.5% of all newborns affected by congenital anomalies each year. Feasible care and proper nutrition during the initial stages post-birth can significantly reduce preterm births by up to three quarters. Furthermore, conditions like neuroblastoma, Krabbe disease, and Gaucher disease pose challenges in older children, necessitating precise medication delivery through advanced infusion pumps to minimize overdose risks and ensure error-free administration.

The chemotherapy segment is anticipated to exhibit the fastest growth rate of 9.28% during the forecast period. According to a recent publication by the American Cancer Society Journal, it has been projected that over 2 million new cancer cases and approximately 611,720 cancer-related deaths will occur in the US alone in 2024. Similarly, the World Health Organization (WHO) reports that cancer is the leading cause of death in the European region, with around 3.7 million new cases and 1.9 million fatalities annually. Fortunately, research suggests that up to 50% of cancers can be prevented by avoiding risk factors, timely diagnosis, and effective treatment. For benign tumors, surgical removal is a viable option; however, malignant ones pose a more significant challenge, as they can invade healthy tissues and require chemotherapy drugs - a complex combination of agents including alkylating agents, nitrosoureas, antimetabolites, antitumor antibiotics, corticosteroids, etc. Chemotherapy is commonly administered intravenously to patients or through capsules, with the dosage tailored to the severity of the cancer, necessitating precise controlled delivery via intravenous infusion pumps. The rising incidence of cancer is expected to drive demand for intravenous infusion pumps, thereby bolstering the overall

End-use Insights

In the healthcare sector, hospitals dominate the market with a substantial 40.3% share in 2024, primarily driven by the widespread adoption of intravenous infusion pumps. These pumps play a critical role in delivering medications, fluids, and nutrients to patients in various hospital settings, including emergency departments, ICUs, operating rooms, and patient wards. The versatility of infusion pumps is evident in their application across different medical conditions, such as chemotherapy administration and fluid hydration for critically ill patients. The American Hospital Association notes that there are currently 6,093 hospitals in the U.S., underscoring the significant demand for these pumps. The need for precise and controlled administration of medications like antibiotics, pain management drugs, and chemotherapy agents is a key driver of this market trend. As a result, infusion pumps continue to be an essential tool in modern healthcare settings, offering improved patient outcomes and streamlined clinical workflows.

 

Homecare settings are poised to experience rapid growth at an astonishing 8.45% CAGR, solidifying their position as a vital component in the administration of IV infusion pumps. This technology empowers patients to receive life-saving medical treatments from the comfort of their own homes, greatly enhancing their overall well-being. For individuals requiring prolonged, consistent therapies, IV infusion pumps have proven to be indispensable tools. These devices enable precise, controlled medication delivery without the need for frequent hospital visits, thus transforming the treatment experience into a more comfortable and convenient one. Furthermore, homecare settings are reaping significant benefits from the flexibility offered by various types of infusion pumps. Ambulatory infusion pumps, designed with portability in mind, allow patients to maintain their daily routines while receiving treatment, making chronic illness management significantly more manageable. Companies like Micrel Medical Devices SA are addressing this need with innovative solutions, such as the Micropump MP mlh+ Multi Syringe, an infusion pump specifically tailored for homecare treatments in pain management and immunoglobulin therapy.

Regional Insights

The North America intravenous infusion pump market is poised for significant growth, with a dominant share of 56.6% in revenue by 2024. This upward trend can be attributed to the region's robust medical infrastructure, increasing prevalence of chronic diseases, and advancements in infusion technology. Additionally, favorable insurance and medical device reimbursement policies, combined with strong local presence of key manufacturers and major exporters of infusion pumps, are expected to drive market growth over the forecast period.

U.S. Intravenous Infusion Pump Market Trends

The US intravenous infusion pumps market is witnessing steady growth as the government prepares to introduce more stringent regulations and adopt new standards for safer and more efficient practices. This progress is being driven by the improvement of national standards of care, including the Infusion Therapy Standards of Practice and Policies and Procedures for Infusion Nursing, alongside enhancements to individual care providers' policies. Furthermore, new product launches and FDA approvals are contributing significantly to market growth. For instance, in April 2024, Baxter secured U.S. FDA clearance for its Novum IQ large volume infusion pump and Dose IQ safety software, marking an advancement in connected and intelligent infusion therapy that ultimately boosts patient safety and care efficiency.

Key North America And Europe Intravenous Infusion Pumps Company

Several prominent firms are dominating this sector, including Baxter B. Braun Melsungen AG, and BD among others. The company's primary approach revolves around comprehensively assessing major competitors' strengths and weaknesses, recognizing future market shifts, opportunities, and obstacles, and proactively making decisions based on in-depth insights into emerging technologies and shifting consumer inclinations. For example, Micrel Medical Devices SA is an emerging contender in the intravenous infusion pumps market, actively seeking to capitalize on specialized technologies to establish a distinct identity among its peers.

Key North America And Europe Intravenous Infusion Pumps Companies:

• Baxter
• B. Braun Melsungen AG
• Fresenius Kabi AG
• ICU Medical, Inc. (Smiths Medical)
• Micrel Medical Devices SA
• Boston Scientific Corporation
• BD
• Terumo Corporation
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Moog Inc.
• IRadimed Corporation
• CODAN Companies
• Arcomed

Recent Developments

• In November 2024, ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. announced a joint venture to enhance supply chain resiliency and innovation in the North American IV solutions market. Combining Otsuka’s extensive global manufacturing capabilities with ICU Medical’s strong North American production and distribution, the partnership aims to deliver advanced IV pumps and consumables to healthcare providers. The agreement includes a USD 200 million upfront payment from OPF to ICU Medical, with additional performance-based milestones and long-term collaboration plans.

• In January 2024, Lemer Pax, a global leader in radiation protection, signed a partnership with ICU Medical, a leader in infusion systems, to distribute the Plum 360 pump in the French nuclear medicine sector to expand its sales in the European market.

North America And Europe Intravenous Infusion Pumps Market Report Scope

Report Attribute	Details
Market size value in 2025	USD 4.78 billion
Revenue forecast in 2030	USD 7.06 billion
Growth Rate	CAGR of 8.10% from 2025 to 2030
Actual data	2018 - 2024
Forecast period	2025 - 2030
Quantitative units	Revenue in USD million/billion and CAGR from 2025 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Product, disease indication, end-use, region
Regional scope	North America, Europe
Country scope	U.S.; copyright; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway.
Key companies profiled	Baxter, B. Braun Melsungen AG, Fresenius Kabi AG, ICU Medical, Inc. (Smiths Medical), Micrel Medical Devices SA, Boston Scientific Corporation, BD, Terumo Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. , Moog Inc. , IRadimed Corporation, CODAN Companies, Arcomed
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

North America And Europe Intravenous Infusion Pumps Market Report Segmentation

This comprehensive report offers a detailed outlook on regional and country-level revenue growth, as well as an in-depth analysis of the latest industry trends across various sub-segments from 2018 to 2030. The study provides granular segmentation for the North America and Europe intravenous infusion pumps market by product, disease indication, end-use, and region, offering a nuanced understanding of the market's dynamics.

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Volumetric Infusion Pumps

  • Syringe Infusion Pumps

  • Ambulatory Infusion Pumps

  • Patient-Controlled Analgesia Infusion Pumps

  • Implantable Infusion Pumps

  • Others

• Disease Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Diabetes

  • Gastroenterology

  • Analgesia/Pain Management

  • Pediatrics/Neonatology

  • Hematology

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Homecare

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • copyright

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway